The Anthem Biosciences IPO has emerged as a significant event in India’s stock market, capturing the attention of retail investors, institutional investors, and industry analysts alike. Launched on July 14, 2025, this ₹3,395 crore Offer for Sale (OFS) by Anthem Biosciences Limited, a Bengaluru-based Contract Research, Development, and Manufacturing Organization (CRDMO), offers a unique investment opportunity in the fast-growing pharmaceutical and biotech sectors. In this SEO-optimized blog, we explore the Anthem Biosciences IPO, its key details, financial information, allotment status, and whether it’s a worthwhile investment for retail investors. With a focus on drug discovery, development, and manufacturing, this IPO positions Anthem as a leader in the CRDMO space.
Anthem Biosciences: A Leader in CRDMO
Anthem Biosciences, also known as Anthem Biosciences Ltd, was established in 2006 and is a technology-focused Contract Research, Development, and Manufacturing Organization. The company provides integrated services across the drug life cycle, specializing in both New Chemical Entities (NCEs) and New Biological Entities (NBEs). Serving over 550 clients across 44+ countries, including the U.S., Europe, and Japan, Anthem caters to large pharmaceutical companies, small pharmaceutical firms, and emerging biotech firms. Its expertise lies in drug discovery, development, and commercial manufacturing, with a strong emphasis on probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
The company operates two state-of-the-art manufacturing facilities in Bommasandra and Harohalli, Karnataka, with a third facility under construction. Anthem’s differentiated business model, particularly its Fee-for-Service (FFS) approach, boasts a 96.76% success rate as of FY25, delivering high-quality solutions to clients. Its focus on manufacturing practices, including green chemistry, flow chemistry, and biotransformation, positions it as a pioneer in regulated markets.
Anthem Biosciences Ltd: IPO Overview
The Anthem Biosciences IPO is a Mainboard IPO listed on the BSE and NSE, with a tentative listing date of July 21, 2025. Here are the key details:
Issue Size: ₹3,395 crore, comprising an Offer for Sale of 5.96 crore equity shares with a face value of ₹2 each. As a 100% OFS, the company will not receive proceeds; all funds, after deducting offer-related expenses and relevant taxes, will go to the selling shareholders.
IPO Price Band: ₹540 to ₹570 per share, with a minimum lot size of 26 shares, requiring a minimum investment of ₹14,820 for retail investors.
Issue Structure: 50% reserved for Qualified Institutional Buyers (QIB), 15% for Non-Institutional Investors (NII), and 35% for the NSE retail quota. Shares worth ₹8.25 crore are reserved for eligible employees, who receive a ₹50 discount per share.
Anchor Investors: The company raised ₹1,016 crore from 60 anchor investors, including Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, PineBridge Global Funds, Amundi Funds, HDFC Mutual Fund, and ICICI Prudential MF, at ₹570 per share on July 11, 2025.
Book-Running Lead Managers: JM Financial Ltd, Citigroup Global Markets India, J.P. Morgan India, and Nomura Financial Advisory and Securities (India).
Registrar: KFin Technologies Limited.
Allotment Date: Expected on July 17, 2025, with shares credited to demat accounts and refunds processed by July 18, 2025.
Listing Date: Tentative listing on July 21, 2025, on BSE and NSE.
The IPO’s objective is to enhance visibility, brand image, and liquidity through stock market listing, with no fresh capital infusion due to the OFS structure.
Anthem Biosciences IPO Allotment and Online Application
Anthem Biosciences IPO Online Application
To apply for the Anthem Biosciences IPO, follow these steps:
Log in to your demat account via Tradejini’s Cubeplus platform
Navigate to the IPO section, select Anthem Biosciences Limited, and enter the
number of lots.Provide your UPI ID and apply.
Approve the UPI mandate on your banking app to block funds.
Financial Information: Anthem Biosciences’ Performance
Anthem Biosciences Ltd has demonstrated robust financial performance, positioning it as a leader among Indian CRDMOs. Below are key financial metrics:
FY25: Revenue of ₹1,930.29 crore, up 30% from ₹1,483.07 crore in FY24. Profit after tax (PAT) grew 23% to ₹451.26 crore from ₹367.31 crore.
FY23: Revenue of ₹1,134 crore and PAT of ₹385.2 crore, driven by exceptional income adjustments.
Growth Metrics: Revenue CAGR of 32%, EBITDA CAGR of 25%, and adjusted PAT CAGR of 18% from FY23 to FY25.
Profitability: EBITDA margins of approximately 37%, reflecting strong operational efficiency.
Valuation: Market cap of ₹31,867.39 crore at the upper IPO price band of ₹570, with a P/E ratio of 70.9x and EV/EBITDA of 45x based on FY25 earnings.
Promoter Holding: Post-IPO equity dilution will reduce promoter holding from 76.88% to 74.69%.
Anthem’s highest revenue growth among Indian and global peers in FY25, coupled with its focus on small molecules and biologics, underscores its strong market position.
Why Invest in the Anthem Biosciences IPO?
Strengths
Leadership in CRDMO: Anthem is one of the few companies in India with integrated services for drug discovery, development, and commercial manufacturing, supporting both chemical entities and biological entities.
Global Reach: Serves over 550 clients, including large pharmaceutical companies like Bayer AG and emerging biotech firms, across 44+ countries, ensuring diversified revenue streams.
Technology-Focused: Expertise in advanced modalities like RNAi, antibody-drug conjugates (ADCs), peptides, lipids, and oligonucleotides, supported by manufacturing practices like biotransformation and flow chemistry.
Expansion Plans: Anthem aims to increase its synthesis and fermentation capacity by 50% over the next 12–18 months, capitalizing on the global shift away from Chinese suppliers.
Brokerage Support: Firms like Anand Rathi and SBI Securities recommend subscribing, citing Anthem’s differentiated business model and high-quality solutions.
Risks
High Valuation: The P/E ratio of 70.9x is a premium compared to peers like Sai Life Sciences, Syngene International, and Divi’s Laboratories, potentially limiting short-term gains.
Client Concentration: Approximately 70% of revenue comes from the top five clients, posing a risk if relationships falter.
OFS Structure: The absence of fresh capital infusion may concern investors seeking growth-funded businesses.
Regulatory Risks: Evolving compliance requirements in regulated markets could impact operational efficiency.
Debt-Funded Capex: Significant debt for expansion may strain financial metrics if not managed effectively.
Anthem Biosciences IPO List: Competitive Landscape
Anthem Biosciences operates in a competitive CRDMO space, with listed peers including Sai Life Sciences, Syngene International, Suven Life Sciences, and Divi’s Laboratories. Its highest revenue growth among peers and leadership in fermentation-based APIs give it a competitive edge. The company’s success-based FFS model and long-term client relationships enhance its appeal to small pharmaceutical and emerging biotech firms.
Should You Subscribe to the Anthem Biosciences IPO?
The Anthem Biosciences IPO presents an opportunity to invest in a technology-focused Contract Research, Development, and Manufacturing Organization with strong growth prospects. Its financial performance, global client base, and focus on drug discovery, development, and commercial manufacturing make it attractive for long-term investment decisions. However, the high P/E ratio, client concentration risk, and lack of fresh proceeds require caution.
Final Verdict
Retail Investors: Subscribe if you’re comfortable with the premium valuation and believe in Anthem’s growth in the CRDMO sector.
Long-Term Investors: Consider subscribing for exposure to small molecules and biologics, supported by Anthem’s expansion plans and robust margins.
Conclusion
The Anthem Biosciences IPO is a landmark offering in India’s stock market, providing retail investors and institutions access to a leading CRDMO with a focus on drug discovery, development, and manufacturing. While its financial information highlights strong growth and profitability, the OFS structure and high valuation warrant careful evaluation. Investors should consult financial advisors, review the Red Herring Prospectus (RHP) on SEBI, BSE, or NSE websites, and monitor allotment status post-subscription.
For updates on the Anthem Biosciences IPO list, allotment date, or listing date, visit the KFin Technologies Limited website or trusted platforms like BSE and NSE. Stay informed and make calculated investment decisions to capitalize on this opportunity in the pharmaceutical and biotech sectors.
Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.
© 2025 — Tradejini. All Rights Reserved.
